ATE338134T1 - Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen - Google Patents
Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungenInfo
- Publication number
- ATE338134T1 ATE338134T1 AT92905817T AT92905817T ATE338134T1 AT E338134 T1 ATE338134 T1 AT E338134T1 AT 92905817 T AT92905817 T AT 92905817T AT 92905817 T AT92905817 T AT 92905817T AT E338134 T1 ATE338134 T1 AT E338134T1
- Authority
- AT
- Austria
- Prior art keywords
- sequences
- human
- nucleotide sequences
- sequences encoding
- cell receptors
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000054584 human Y acceptor Human genes 0.000 abstract 1
- 108700023876 human Y acceptor Proteins 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Test And Diagnosis Of Digital Computers (AREA)
- Computer And Data Communications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9101487A FR2672616B1 (fr) | 1991-02-08 | 1991-02-08 | Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs de lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques. |
| FR9104527A FR2675156B1 (fr) | 1991-04-12 | 1991-04-12 | Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs des lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE338134T1 true ATE338134T1 (de) | 2006-09-15 |
Family
ID=26228502
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92905817T ATE338134T1 (de) | 1991-02-08 | 1992-02-07 | Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen |
| AT06009929T ATE504650T1 (de) | 1991-02-08 | 1992-02-07 | Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06009929T ATE504650T1 (de) | 1991-02-08 | 1992-02-07 | Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US5817511A (de) |
| EP (2) | EP0529033B1 (de) |
| JP (1) | JPH05509234A (de) |
| KR (1) | KR100242278B1 (de) |
| AT (2) | ATE338134T1 (de) |
| AU (1) | AU660660B2 (de) |
| CA (1) | CA2079879C (de) |
| DE (2) | DE69233652T2 (de) |
| DK (1) | DK0529033T3 (de) |
| ES (1) | ES2271940T3 (de) |
| IE (1) | IE920413A1 (de) |
| WO (1) | WO1992013949A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2072356A1 (en) * | 1989-12-29 | 1991-06-30 | James L. Urban | Diagnosis and treatment of diseases |
| US7294712B2 (en) * | 1990-06-04 | 2007-11-13 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| ATE338134T1 (de) * | 1991-02-08 | 2006-09-15 | Aventis Pharma Sa | Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen |
| KR100227303B1 (ko) * | 1991-02-12 | 1999-12-01 | 장-끌로드 비에이으포스 | 인체 t 임파구 수용체의 베타 사슬의 가변성 영역을 코딩하는 뉴클레오티드 서열, 대응하는 펩티드 세그먼트 및 진단 및 치료 용도 |
| DE4225569C2 (de) * | 1992-08-03 | 1996-04-25 | Max Planck Gesellschaft | Verwendung einer Sonde zur Tumordiagnostik oder Tumortherapie |
| JP3875730B2 (ja) * | 1993-02-22 | 2007-01-31 | サノフィ・アベンティス株式会社 | 自己免疫疾患の予防治療剤 |
| CA2188182A1 (en) * | 1994-04-18 | 1995-10-26 | Steven M. Friedman | Conserved t-cell receptor sequences |
| EP1095948A1 (de) * | 1999-10-28 | 2001-05-02 | Universitätsklinikum Freiburg | Idiotype Impstoffe |
| KR100363271B1 (ko) * | 2000-06-12 | 2002-12-05 | 주식회사 동진쎄미켐 | 포토레지스트 리무버 조성물 |
| US20060275747A1 (en) * | 2001-12-07 | 2006-12-07 | Hardy Stephen F | Endogenous retrovirus up-regulated in prostate cancer |
| ATE545651T1 (de) | 2002-06-13 | 2012-03-15 | Novartis Vaccines & Diagnostic | Vektoren zur expression von hml-2-polypeptiden |
| CA2490903A1 (en) * | 2002-07-03 | 2004-01-15 | Institute For Scientific Research, Inc. | Compositions and methods for the detection of human t cell receptor variable family gene expression |
| FR2863274B1 (fr) | 2003-12-05 | 2012-11-16 | Commissariat Energie Atomique | Procede d'evaluation quantitative d'un rearrangement ou d'une recombinaison genetique ciblee d'un individu et ses applications. |
| EP2044949A1 (de) | 2007-10-05 | 2009-04-08 | Immutep | Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion |
| EP2449103B1 (de) * | 2009-06-29 | 2016-08-03 | California Institute of Technology | Isolierung von unbekannten neu angeordneten t-zellen-rezeptoren aus einzelnen zellen |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| US9683048B2 (en) | 2014-01-24 | 2017-06-20 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| JP6576962B2 (ja) | 2014-03-14 | 2019-09-18 | ノバルティス アーゲー | Ｌａｇ−３に対する抗体分子およびその使用 |
| US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874845A (en) * | 1984-06-13 | 1989-10-17 | Massachusetts Institute Of Technology | T lymphocyte receptor subunit |
| EP0200350A3 (de) * | 1985-04-15 | 1987-05-13 | The Ontario Cancer Institute | Nukleinsäure mit Code für ein T-Zellen-Antigenrezeptor-Polypeptid |
| WO1987003600A1 (en) * | 1985-12-03 | 1987-06-18 | T Cell Sciences, Inc. | Cell-free t cell antigen receptor and its clinical utilities |
| US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| US5216132A (en) * | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
| ATE338134T1 (de) * | 1991-02-08 | 2006-09-15 | Aventis Pharma Sa | Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen |
-
1992
- 1992-02-07 AT AT92905817T patent/ATE338134T1/de active
- 1992-02-07 CA CA002079879A patent/CA2079879C/fr not_active Expired - Lifetime
- 1992-02-07 WO PCT/FR1992/000111 patent/WO1992013949A1/fr not_active Ceased
- 1992-02-07 DK DK92905817T patent/DK0529033T3/da active
- 1992-02-07 JP JP4505541A patent/JPH05509234A/ja active Pending
- 1992-02-07 ES ES92905817T patent/ES2271940T3/es not_active Expired - Lifetime
- 1992-02-07 EP EP92905817A patent/EP0529033B1/de not_active Expired - Lifetime
- 1992-02-07 EP EP06009929A patent/EP1721978B1/de not_active Expired - Lifetime
- 1992-02-07 IE IE041392A patent/IE920413A1/en unknown
- 1992-02-07 DE DE69233652T patent/DE69233652T2/de not_active Expired - Lifetime
- 1992-02-07 KR KR1019920702482A patent/KR100242278B1/ko not_active Expired - Lifetime
- 1992-02-07 AT AT06009929T patent/ATE504650T1/de not_active IP Right Cessation
- 1992-02-07 DE DE69233804T patent/DE69233804D1/de not_active Expired - Lifetime
- 1992-02-07 AU AU13603/92A patent/AU660660B2/en not_active Expired
-
1995
- 1995-04-19 US US08/348,572 patent/US5817511A/en not_active Expired - Lifetime
-
1996
- 1996-03-22 US US08/620,467 patent/US5798231A/en not_active Expired - Lifetime
-
1998
- 1998-03-12 US US09/041,090 patent/US6114516A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1721978A1 (de) | 2006-11-15 |
| WO1992013949A1 (fr) | 1992-08-20 |
| EP0529033B1 (de) | 2006-08-30 |
| AU660660B2 (en) | 1995-07-06 |
| KR100242278B1 (ko) | 2000-02-01 |
| DE69233804D1 (de) | 2011-05-19 |
| IE920413A1 (en) | 1992-08-12 |
| US5798231A (en) | 1998-08-25 |
| DK0529033T3 (da) | 2007-01-08 |
| EP0529033A1 (de) | 1993-03-03 |
| AU1360392A (en) | 1992-09-07 |
| CA2079879A1 (fr) | 1992-08-09 |
| US6114516A (en) | 2000-09-05 |
| US5817511A (en) | 1998-10-06 |
| CA2079879C (fr) | 2007-11-06 |
| ATE504650T1 (de) | 2011-04-15 |
| DE69233652T2 (de) | 2007-09-27 |
| DE69233652D1 (de) | 2006-10-12 |
| JPH05509234A (ja) | 1993-12-22 |
| ES2271940T3 (es) | 2007-04-16 |
| EP1721978B1 (de) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE504650T1 (de) | Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen | |
| BR9007197A (pt) | Cadeia pesada,cadeia leve e molecula de anticorpo,sequencia de dna,vetor de clonagem,celula hospedeira,processos para produzir uma sequencia de anticorpo e um produto de anticorpo,composicao terapeutica e processo de terapia ou diagnose | |
| ATE131871T1 (de) | Rezeptoren für tumornekrosisfaktor-alpha und - beta | |
| Krangel et al. | Structurally divergent human T cell receptor γ proteins encoded by distinct Cγ genes | |
| DE69428214D1 (de) | Transformierender wachstumsfaktor alpha h1 | |
| LU91411I2 (fr) | Panitumumab et ses dérivés pharmaceutiquement acceptables (VECTIBIX) | |
| DE3782259D1 (de) | Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung. | |
| JPWO2021202678A5 (de) | ||
| DE69737978D1 (de) | Als 2f1 bezeichnetes rezeptorprotein | |
| DK0669979T3 (da) | C-C CKR-1, kemokinreceptor | |
| HUT63652A (en) | Process for producing cd44 surface protein variants, dna sequences encoding them and antibodies against them, as well as their application in diagnosis and therapy | |
| ATE173023T1 (de) | Dna-sequenzen kodierend für das polypeptid gelonin | |
| Suran et al. | N-terminal sequences of heavy and light chains of leopard shark immunoglobulins: evolutionary implications. | |
| Negro et al. | Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli | |
| KR970070198A (ko) | 항-파스 재조합 항체 및 이에 대한 디엔아이 | |
| ATE252638T1 (de) | Das humane jtvi-gen überlappt mit dem pms2-gen | |
| ATE283368T1 (de) | Für die glutamatabhängigen chloridkanäle kodierende dna | |
| Fellah et al. | Structure and diversity of the T-cell receptor α chain in the Mexican axolotl | |
| DE69329190D1 (de) | Autotaxin : ein das selbständige zellbewegungsvermögen stimulierendes protein nützlich in der krebs-diagnostik und therapie | |
| Kino et al. | A novel chain of basement membrane-associated collagen as revealed by biochemical and immunohistochemical characterizations of the epitope recognized by a monoclonal antibody against human placenta basement membrane collagen | |
| ATE175719T1 (de) | Epididymis-spezifische polypeptide und deren verwendung | |
| KR860006484A (ko) | 단백질 또는 당단백질의 제조방법 | |
| ATE229983T1 (de) | Maspin- ein neues serpin mit tumor unterdrückender aktivität | |
| US5977321A (en) | Heterodimeric T lymphocyte receptor subunit | |
| JPS6410998A (en) | Tumor cell inhibitory factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0529033 Country of ref document: EP |